Asacol (mesalamine)

Procter & Gamble

Approval Status
Approved August 1997

Treatment for
ulcerative colitits


Asacol (mesalamine) was approved by the Food and Drug Administration in August 1997. Asacol tablets are indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis.

Side effects include headaches, abdominal pain, eructation, and nausea.

Asacol (mesalamine) Drug Information

The Asacol (mesalamine) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top